Braveheart Bio Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Cash & Equivalents	80.58	89.16
Cash & Short-Term Investments	80.58	89.16
Cash Growth	-	-
Prepaid Expenses	0.5	0.12
Total Current Assets	81.07	89.28
Other Long-Term Assets	0.07	0.07
Total Assets	81.88	89.35
Accounts Payable	7.74	1.06
Accrued Expenses	1.89	1.18
Other Current Liabilities	-	3
Total Current Liabilities	10	5.24
Other Long-Term Liabilities	0.09	0.09
Total Liabilities	10.39	5.33
Common Stock	0	0
Additional Paid-In Capital	1.94	0.18
Retained Earnings	-80.33	-66.05
Total Common Equity	-78.39	-65.87
Shareholders' Equity	71.49	84.02
Total Liabilities & Equity	81.88	89.35
Net Cash (Debt)	79.91	89.16
Net Cash Growth	-	-
Net Cash Per Share	2.62	5.30
Filing Date Shares Outstanding	30.48	29.28
Total Common Shares Outstanding	30.48	29.28
Working Capital	71.07	84.04
Book Value Per Share	-2.57	-2.25
Tangible Book Value	-78.39	-65.87
Tangible Book Value Per Share	-2.57	-2.25

SEC Filings: 10-K · 10-Q